Kardigan, Inc.

Analyst research, target price, syndicate analytics, and valuation sections are included with an active subscription. View plans

Investment Snapshot

S-1 All Filings

Symbol

KARD

Offer Range

—

Shares Offered

—

Total Shares Post-IPO

40.4M

Market Cap

—

Target Price

$00.00

Implied Upside vs Midpoint

$00.00

Use of Proceeds

—

Valuation & Price Target

████████████████████

Business & Product Moat

████████████████████

Company Description (Source)

Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Our mission is to develop multiple targeted cardiovascular treatments in parallel that bring people with cardiovascular diseases closer to the cures they deserve. We leverage deep domain expertise in cardiovascular biology, patient data, and advanced analytics to accelerate drug discovery and development, aiming to deliver impactful therapies efficiently and at scale. Our management team includes leaders from MyoKardia, Inc. (“MyoKardia”) with a proven track record in cardiovascular drug development, including the successful development and approval of mavacamten for hypertrophic cardiomyopathy. Cardiovascular disease is the leading cause of death worldwide, yet innovation has lagged due to drug development focused on broad, downstream, symptom-focused approaches despite disease heterogeneity and genetic variability, resulting in incremental advances and lengthy clinical trials. Kardigan is committed to overcoming these challenges by advancing precision medicines that target the fundamental drivers of cardiovascular conditions, aiming to deliver meaningful improvements in patient outcomes. --- We were incorporated under the laws of the State of Delaware in August 2023 under the name EnCarda, Inc., and changed our name to Kardigan, Inc. in December 2024. Our principal executive offices are located at 506 Carnegie Center Drive, Suite 201, Princeton, NJ 08540, and our telephone number is (415) 573-3220. We have two subsidiaries, Rancho Santa Fe Bio, Inc., formed in October 2019 under the laws of the State of Delaware, and Prolaio, Inc., formed in November 2021 under the laws of the State of Delaware. Our website address is www.kardigan.bio.

Competitor Set

████████████████████